Development Of New Therapy to Combat Tuberculosis Induced Inflammation

Tuberculosis (TB) is a major global health problem. TB disease induces a strong pro-inflammatory response, which can lead to irreversible lung damage, even after successful antibiotic therapy. This thesis investigated the effectiveness of two anti-inflammatory agents, Tristetraprolin (TTP) and FhHDM-1, to reduce lung inflammation during TB infection. A mouse model expressing active TTP was infected with M. tuberculosis. TTP mutant mice showed reduced lung inflammation during early infection. Next studies examining the FhHDM-1 peptide showed it was able to inhibit the secretion of the pro-inflammatory cytokines, TNF and IL-6, in human macrophages. Treatment of M. tuberculosis infected mice with FhHDM-1 also significantly reduced lung inflammation without reducing control of the bacteria. This research identified two pathways to reduce inflammation during M. tuberculosis infection. Further studies with these anti-inflammatories will hopefully lead to new treatments to reduce TB induced lung damage.

Author dc:creator

• Le, Giang Hoang Bao

Statement dc:rights

• info:eu-repo/semantics/embargoedAccess
• The author owns the copyright in this thesis including all reproduction and reuse rights for the work. The work may not be altered without the permission of the copyright owner. Attribution is essential when quoting or paraphrasing from this thesis.
• © 2024 Giang Hoang Bao Le
• au.edu.uts.lib/cph

Language dc:language.iso

en_US

Handle dc:identifier.uri

http://hdl.handle.net/10453/187347

OAI identifier oai:identifier

oai:opus.lib.uts.edu.au:10453/187347